Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombol… (NCT07665320) | Clinical Trial Compass
RecruitingNot Applicable
Impedance Plethysmography Based Deep Vein Thrombosis Monitoring During Catheter-directed Thrombolysis
Finland40 participantsStarted 2025-07-17
Plain-language summary
The purpose of this study is to collect data on blood circulation using a multi-frequency impedance plethysmography device developed in the ThrombUS+ project. Impedance plethysmography (IPG) is a non-invasive method that measures changes in blood volume using electrodes placed on the skin. The collected data will be used for device development, the improvement of diagnostic data analysis methods, and AI training.
A total of 40 participants will be recruited for this study, with 20 healthy volunteers in Tampere University and 20 patients undergoing thrombolytic therapy for DVT at Tampere University Hospital.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria for Patients group:
* Age: 18 or older;
* DVT detected on other lower limb;
* Suitable for CDT treatment;
* Ability to give informed consent;
* Volunteering for the study.
Exclusion Criteria for Patients group:
* Age under 18 years;
* Inability to give informed consent;
* Denial;
* Too injured skin in the measurement area
Inclusion Criteria for Healthy volunteers group:
* Age: 18 or older;
* Ability to give informed consent;
* Volunteering for the study
Exclusion Criteria for Healthy volunteers group:
* Diagnosed DVT in lower limbs;
* Age under 18 years;
* Inability to give informed consent;
* Denial;
* Too injured skin in the measurement area.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Impedance plethysmography (IPG) data during CDT treatment
Timeframe: From enrollment to the end of the CDT treatment (up to 2 days)
2
Impedance plethysmography (IPG) data from healthy volunteers
Timeframe: From enrollment to the end of measurements (up to 2 hours)